Kezar Life Sciences

Kezar Life Sciences, Inc. focuses on the development of therapies for chronic autoimmune diseases.70 mn.Kezar Life Sciences is primarily focused on the development of innovative small molecule therapies aimed at regulating protein dysregulation that leads to chronic diseases, particularly autoimmune disorders. Their core product, Zetomipzomib (KZR-616), represents a first-in-class molecule designed to selectively inhibit the immunoproteasome, targeting specific cellular pathways involved in autoimmune conditions. The company aims to address limitations of traditional treatments by offering therapies that modulate the immune response rather than directly suppressing it.Kezar Life Sciences generates revenue primarily through partnerships and collaborations with pharmaceutical companies and healthcare organizations involved in clinical trial development and product commercialization. The revenue structure may entail milestone payments and royalties derived from the successful development and commercialization of their flagship product, Zetomipzomib. Such transactions typically occur as the product progresses through various phases of clinical trials, leading to eventual market entry.Kezar Life Sciences is focused on continuing the development of Zetomipzomib and plans to explore additional new product candidates aimed at autoimmune diseases.00 mn to support ongoing clinical trials and product development initiatives.

1. Series B

   Jul 21, 2017

   Amount

   $50M

   Investors

   Locked

2. Series A

   Jun 16, 2015

   Amount

   $23M

   Investors

   Locked